Sinovac Schedules Conference Call and Webcast for Fourth Quarter and Full Year Unaudited Financial Results

Sinovac Schedules Conference Call and Webcast for Fourth Quarter and Full Year
                         Unaudited Financial Results

PR Newswire

BEIJING, April 2, 2013

BEIJING, April 2, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a
leading provider of vaccines in China, today announced that it will release
its unaudited financial results for the fourth quarter and full year ended
December 31, 2012, before market on Thursday, April 18, 2013. The Company
will host a conference call on Thursday, April 18, 2013, at 8:00 a.m. EDT
(April 18, 2013, at 8:00 p.m. China Standard Time) to review the Company's
financial results and provide an update on recent corporate developments.

To access the conference call, please dial 1-877-407-4018 (USA) or
1-201-689-8471 (International). A replay of the call will be available from
11 a.m. EDT on April 18, 2013 to May 2, 2013 at midnight. To access the
replay, please dial 1-877-870-5176 (USA) or 1-858-384-5517 (International) and
reference the replay pin number 411774.

A live audio webcast of the call will also be available from the investors
section on the corporate web site at www.sinovac.com. A webcast replay can be
accessed on the corporate website beginning April 18, 2013, and the replay
will remain available for 30 days.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses
on research, development, manufacturing and commercialization of vaccines that
protect against infectious diseases including hepatitis A and B, seasonal
influenza, H5N1 pandemic influenza and mumps, as well as animal rabies
vaccine. In 2009, Sinovac was the first company worldwide to receive approval
for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for the
Chinese Central Government, pursuant to the government-stockpiling program.
The Company is also the only supplier of the H5N1 pandemic influenza vaccine
to the government-stockpiling program. Sinovac is developing a number of new
pipeline vaccines including vaccines for enterovirus 71 (against hand, foot,
and mouth disease), pneumonia, varicella and rubella. Sinovac sells its
vaccines mainly in China and exports selected vaccines to Mongolia, Nepal, and
the Philippines.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are
made under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar statements.
Among other things, the business outlook and quotations from management in
this press release contain forward-looking statements. Statements that are not
historical facts, including statements about Sinovac's beliefs and
expectations, are forward-looking statements. Forward-looking statements
involve inherent risks and uncertainties. A number of important factors could
cause actual results to differ materially from those contained in any
forward-looking statement. Sinovac does not undertake any obligation to update
any forward-looking statement, except as required under applicable law.

Helen Yang
Sinovac Biotech Ltd.
Tel: +86-10-8279-9871
Fax: +86-10-6296-6910
Email: ir@sinovac.com

Investors:
Stephanie Carrington
The Ruth Group
Tel: +1-646-536-7017
Email: scarrington@theruthgroup.com

Media:
Aaron Estrada
The Ruth Group
Tel: +1-646-536-7028
Email: aestrada@theruthgroup.com

SOURCE Sinovac Biotech Ltd.

Website: http://www.sinovac.com
 
Press spacebar to pause and continue. Press esc to stop.